Perrigo (NYSE:PRGO)‘s stock had its “buy” rating reiterated by stock analysts at Canaccord Genuity in a research report issued on Wednesday. They presently have a $100.00 price objective on the stock. Canaccord Genuity’s price target would indicate a potential upside of 10.06% from the company’s current price.
A number of other research analysts have also weighed in on the stock. Leerink Swann began coverage on shares of Perrigo in a research note on Tuesday, January 2nd. They issued a “market perform” rating and a $90.00 price target on the stock. Morgan Stanley lifted their price target on shares of Perrigo from $79.00 to $92.00 and gave the company an “equal weight” rating in a research note on Friday, November 10th. Jefferies Group reaffirmed a “hold” rating and issued a $81.00 price target on shares of Perrigo in a research note on Friday, November 10th. Argus raised shares of Perrigo from a “hold” rating to a “buy” rating and set a $93.00 price target on the stock in a research note on Friday, December 8th. Finally, Cantor Fitzgerald set a $107.00 price target on shares of Perrigo and gave the company a “buy” rating in a research note on Friday, January 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company’s stock. Perrigo currently has an average rating of “Hold” and an average target price of $92.00.
Perrigo (NYSE:PRGO) opened at $90.86 on Wednesday. The stock has a market cap of $12,930.00, a P/E ratio of -9.92, a P/E/G ratio of 1.94 and a beta of 0.64. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.24 and a current ratio of 1.72. Perrigo has a 1-year low of $63.68 and a 1-year high of $92.75.
Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Thursday, November 9th. The company reported $1.39 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.28. The firm had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.17 billion. Perrigo had a negative net margin of 26.28% and a positive return on equity of 11.60%. The business’s revenue for the quarter was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.65 earnings per share. equities analysts forecast that Perrigo will post 4.88 EPS for the current year.
In related news, VP Todd W. Kingma sold 1,500 shares of the business’s stock in a transaction on Friday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the transaction, the vice president now directly owns 19,565 shares in the company, valued at $1,731,893.80. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP John Wesolowski sold 388 shares of the business’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.20, for a total transaction of $33,833.60. Following the transaction, the executive vice president now owns 248 shares in the company, valued at $21,625.60. The disclosure for this sale can be found here. In the last three months, insiders sold 4,051 shares of company stock worth $355,370. 6.90% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of PRGO. Victory Capital Management Inc. increased its holdings in Perrigo by 3,286.6% during the third quarter. Victory Capital Management Inc. now owns 1,074,770 shares of the company’s stock worth $90,979,000 after buying an additional 1,043,034 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Perrigo by 50.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,846,993 shares of the company’s stock worth $139,485,000 after buying an additional 623,370 shares during the last quarter. Greenlight Capital Inc. increased its holdings in Perrigo by 14.8% during the third quarter. Greenlight Capital Inc. now owns 2,901,032 shares of the company’s stock worth $245,572,000 after buying an additional 374,032 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Perrigo during the second quarter worth $27,377,000. Finally, Gotham Asset Management LLC acquired a new position in Perrigo during the second quarter worth $24,950,000. Institutional investors and hedge funds own 83.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/01/17/perrigos-prgo-buy-rating-reaffirmed-at-canaccord-genuity.html.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.